RayKnowChina Research Map
Shortlist0

Fudan University

复旦大学

ShanghaiUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
3.4%Leads about 1 in 30 of China's research papers on NPC

Led 80 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
13
Research papers it led
80
Trials it led
44
Share of China's trials
7.4%
Share of the world's papers
2.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueInduction / concurrent chemotherapy

Hospitals counted here

  1. Fudan University Shanghai Cancer Center38
  2. Eye & ENT Hospital of Fudan University32
  3. Zhongshan Hospital, Fudan University3
  4. Children's Hospital of Fudan University Counted in the group total1
  5. Huashan Hospital Counted in the group total1
  6. Affiliated ENT Hospital of Fudan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial.2025Journal for immunotherapy of cancerRCTFree full text
  2. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.2024Signal transduction and targeted therapyFree full text
  3. LINC-PINT expression and rs1059698 polymorphism associate with chemoradiotherapy efficacy in Chinese nasopharyngeal carcinoma patients.2025BMC cancerFree full text
  4. Mucosal Flap Reconstruction Enhances Survival in Salvage Endoscopic Nasopharyngectomy for Recurrent Nasopharyngeal Carcinoma: A Propensity-Matched Cohort Study.2025International forum of allergy & rhinology
  5. Artificial intelligence-assisted detection of nasopharyngeal carcinoma on endoscopic images: a national, multicentre, model development and validation study.2025The Lancet. Digital health
Trials on ClinicalTrials.gov6
  1. Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal CarcinomaNot yet recruitingNCT07789158Lead sponsorPhase 2Start 2026-09
  2. Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.RecruitingNCT07781358Lead sponsorPhase 2Start 2026-08
  3. Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal CarcinomaRecruitingNCT07762976Lead sponsorPhase 2Start 2026-08
  4. Individualized Neck Cervical Irradiation Prophylaxis Trial of NPCRecruitingNCT07303023Lead sponsorPhase 3Start 2025-09
  5. Adjuvant vs Surgery Only in Early-stage Recurrent NPCRecruitingNCT06228079Lead sponsorPhase 3Start 2024-06
  6. Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After RadiotherapyRecruitingNCT07067268Lead sponsorPhase 2Start 2024-09

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
3.7%Leads about 1 in 27 of China's research papers on ESCC

Led 109 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
17
Research papers it led
109
Trials it led
53
Share of China's trials
9.3%
Share of the world's papers
2.5%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025
ThemesMolecular markers & genomicsNeoadjuvant & combined treatmentRadiotherapy

Hospitals counted here

  1. Zhongshan Hospital, Fudan University56
  2. Fudan University Shanghai Cancer Center32
  3. Huashan Hospital12
  4. Shanghai Pudong Hospital Counted in the group total1
  5. Hua Shan Hospital, Fudan University1
  6. Shanghai Xuhui Central Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.2023Annals of oncology : official journal of the European Society for Medical OncologyRCT
  2. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.2022JAMA network openRCTFree full text
  3. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Cli2021JAMA surgeryRCTFree full text
  4. Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma.2025The oncologistRCTFree full text
  5. Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring.2025Molecular cancerRCTFree full text
Trials on ClinicalTrials.gov6
  1. PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCCRecruitingNCT07697859Lead sponsorStart 2026-07
  2. An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual ImagingNot yet recruitingNCT07770672Lead sponsorPhase 2Start 2026-08
  3. Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCCRecruitingNCT07403136Lead sponsorPhase 2Start 2026-04
  4. CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCCRecruitingNCT06964568Lead sponsorPhase 3Start 2025-02
  5. Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07054086Lead sponsorStart 2025-03
  6. Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)RecruitingNCT07317609Lead sponsorPhase 1Start 2025-07

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
4.1%Leads about 1 in 25 of China's research papers on HCC ▼ from 5.1%

Led 603 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
20
Research papers it led
603
Trials it led
107
Share of China's trials
7.3%
Share of the world's papers
2.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Hospitals counted here

  1. Zhongshan Hospital, Fudan University408
  2. Huashan Hospital62
  3. Fudan University Shanghai Cancer Center54
  4. Minhang Hospital Counted in the group total14
  5. Jinshan Hospital Counted in the group total5
  6. Huadong Hospital, Fudan University Counted in the group total5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.2025Lancet (London, England)RCT
  2. External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial.2025International journal of radiation oncology, biology, physicsRCT
  3. 3D-CEUS/MRI-CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: a multicenter prospective study of therapeutic response evaluation.2025European radiologyRCT
  4. Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial.2025Liver international : official journal of the International Association for the Study of the LiverRCTFree full text
  5. Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.2025Journal of translational medicineRCTFree full text
Trials on ClinicalTrials.gov6
  1. Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular CarcinomaRecruitingNCT07536789Lead sponsorPhase 2Start 2026-04
  2. A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular CarcinomaRecruitingNCT07328009Lead sponsorPhase 2Start 2026-01
  3. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Lead sponsorStart 2026-07
  4. Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical StudyRecruitingNCT06794073Lead sponsorN/AStart 2026-01
  5. NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCCNot yet recruitingNCT07919717Lead sponsorPhase 2Start 2026-11
  6. The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver TumorsRecruitingNCT07159048Lead sponsorN/AStart 2025-10

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
2.9%Leads about 1 in 35 of China's research papers on Stomach cancer ▼ from 3.9%

Led 281 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
39
Research papers it led
281
Trials it led
88
Share of China's trials
6.0%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025
ThemesEarly detection & endoscopySurgeryImmunotherapy & targeted drugs

Hospitals counted here

  1. Zhongshan Hospital, Fudan University134
  2. Fudan University Shanghai Cancer Center88
  3. Huashan Hospital22
  4. Minhang Hospital9
  5. Shanghai Pudong Hospital Counted in the group total5
  6. Huadong Hospital, Fudan University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).2022Cancer communications (London, England)RCTFree full text
  2. Nutritional support after hospital discharge reduces long-term mortality in patients after gastric cancer surgery: Secondary analysis of a prospective randomized trial.2025Nutrition (Burbank, Los Angeles County, Calif.)RCT
  3. Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01).2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationRCT
  4. Early intravenous branched-chain amino acid-enriched nutrition supplementation in older patients undergoing gastric surgery: a randomized clinical trial.2024Nutrition journalRCTFree full text
  5. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.2023International journal of cancerRCTFree full text
Trials on ClinicalTrials.gov6
  1. An Observational Study on Gastric Cancer in High-risk IndividualsNot yet recruitingNCT07438418Lead sponsorStart 2026-01
  2. A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT07492615Lead sponsorPhase 2Start 2026-01
  3. A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic CancerRecruitingNCT07707531Lead sponsorEarly phase 1Start 2026-06
  4. Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant TreatmentNot yet recruitingNCT07508956Lead sponsorPhase 3Start 2026-06
  5. Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialNot yet recruitingNCT06943794Lead sponsorN/AStart 2026-03
  6. Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJNot yet recruitingNCT07912957Lead sponsorPhase 2Start 2026-11

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
5.2%Leads about 1 in 19 of China's research papers on Hepatoblastoma ▼ from 7.1%

Led 8 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Children's Hospital of Fudan University5
  2. Zhongshan Hospital, Fudan University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
2.3%Leads about 1 in 43 of China's research papers on Retinoblastoma ▲ from 0.9%

Led 7 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
3
Research papers it led
7
Trials it led
3
Share of China's trials
23.1%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 3320242025: 112025

Hospitals counted here

  1. Eye & ENT Hospital of Fudan University6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
7.6%Leads about 1 in 13 of China's research papers on Chordoma ▲ from 3.1%

Led 8 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
1
Share of China's trials
16.7%
Share of the world's papers
1.5%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025

Hospitals counted here

  1. Huashan Hospital4
  2. Fudan University Shanghai Cancer Center3
  3. Fifth People's Hospital of Fudan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.1%Leads about 1 in 87 of China's research papers on Osteosarcoma

Led 26 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
26
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Fudan University Shanghai Cancer Center6
  2. Zhongshan Hospital, Fudan University5
  3. Children's Hospital of Fudan University4
  4. Jinshan Hospital3
  5. Huashan Hospital2
  6. Minhang Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  2. Peri-osteosarcoma adipose computed tomography attenuation and volume for predicting chemotherapy response in pediatric patients.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. ENO1 promotes cancer metastasis via stimulating metabolism reprogramming in osteosarcoma.2025British journal of cancer
  4. Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.2025Biomolecules
  5. Establishment and characterization of a patient-derived metastatic extraskeletal Ewing sarcoma cell line ES-ZSS-1.2024Human cell

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
5.7%Leads about 1 in 17 of China's research papers on Gastrointestinal stromal tumour

Led 30 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
30
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
1.8%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Zhongshan Hospital, Fudan University28

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Endoscopic transmural route for dissection of gastric submucosal tumors with extraluminal growth: experience in two cases.2021GutFree full text
  2. Proteomic Characterization Identifies Clinically Relevant Subgroups of Gastrointestinal Stromal Tumors.2024Gastroenterology
  3. Endoscopic resection for small rectal gastrointestinal stromal tumors: a pilot study.2025BMC gastroenterology
  4. Hidden risk factors for recurrence of jejunoileal Gastrointestinal stromal tumors with low NIH classification: implications for surveillance and adjuvant therapy.2025Journal of translational medicine
  5. A case of quadruple wild-type gastrointestinal stromal tumor with CDC42BPB::NTRK3 fusion and abundant lymphoid infiltration.2025Diagnostic pathology
Trials on ClinicalTrials.gov6
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. RCT of EFTR Versus STER for GIST TreatmentRecruitingNCT07411118Study siteN/AStart 2025-02
  3. A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Study sitePhase 1Start 2018-07
  4. Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GISTStatus unknownNCT02353052Lead sponsorStart 2013-07
  5. Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GISTActive, not recruitingNCT07837271Study siteStart 2026-01
  6. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Study sitePhase 2Start 2020-04

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.8%Leads about 1 in 56 of China's research papers on Neuroblastoma ▼ from 4.3%

Led 20 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
1
Research papers it led
20
Trials it led
1
Share of China's trials
2.4%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025

Hospitals counted here

  1. Children's Hospital of Fudan University11
  2. Eye & ENT Hospital of Fudan University5
  3. Gynecology Hospital, Fudan University2
  4. Huashan Hospital1
  5. Jinshan Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
4.9%Leads about 1 in 20 of China's research papers on Ewing sarcoma ▲ from 2.4%

Led 8 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
2
Share of China's trials
12.5%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Fudan University Shanghai Cancer Center4
  2. Zhongshan Hospital, Fudan University2
  3. Children's Hospital of Fudan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
2.2%Leads about 1 in 45 of China's research papers on Myeloma ▲ from 1.6%

Led 37 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
4
Research papers it led
37
Trials it led
5
Share of China's trials
1.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025
ThemesDiagnosis, MRD & riskDrug combinationsKidney & bone complications

Hospitals counted here

  1. Zhongshan Hospital, Fudan University23
  2. Huashan Hospital5
  3. Huadong Hospital, Fudan University Counted in the group total2
  4. Jinshan Hospital Counted in the group total1
  5. Fifth People's Hospital of Fudan University Counted in the group total1
  6. Shanghai Pudong Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Real-World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15-Year Period.2025Hematological oncology
  2. Advantage of Tolerability following Arsenic Trioxide-VTD vs VRD in newly diagnosed multiple myeloma patients: a prospective, open-label study.2025International journal of medical sciencesFree full text
  3. Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.2024BMC cancerFree full text
  4. Enhanced clinical outcomes with radiotherapy in diagnostically challenging intracranial plasmacytomas: Analysis of 190 cases.2024Cancer medicine
  5. IgE-kappa multiple myeloma with kappa free light chain: a case report.2024Scandinavian journal of clinical and laboratory investigation
Trials on ClinicalTrials.gov6
  1. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Lead sponsorStart 2026-06
  2. A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).RecruitingNCT07638683Lead sponsorPhase 2Start 2026-05
  3. Longitudinal Data Registry of Plasma Cell DyscrasiaRecruitingNCT06760052Lead sponsorStart 2023-03
  4. The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE StudyRecruitingNCT05965115Lead sponsorStart 2023-07
  5. A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingNCT07623798Study sitePhase 3Start 2026-06
  6. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.0%Leads none of China's research papers on B-ALL

Led 0 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
1
Share of China's trials
0.4%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov6
  1. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  2. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  3. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  4. CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHLRecruitingNCT06445803Study sitePhase 1Start 2024-05
  5. Phase Ib Clinical Study of KeynatinibRecruitingNCT04807881Study sitePhase 1Start 2020-09
  6. Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaStatus unknownNCT04173988Lead sponsorEarly phase 1Start 2020-01

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.7%Leads under 1 in 100 of China's research papers on Aplastic anaemia

Led 3 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025
ThemesImmunosuppressive treatment

Hospitals counted here

  1. Zhongshan Hospital, Fudan University Counted in the group total1
  2. Huashan Hospital Counted in the group total1
  3. Children's Hospital of Fudan University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.5%Leads under 1 in 100 of China's research papers on HLH ▼ from 1.1%

Led 2 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
1
Share of China's trials
2.1%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025
ThemesDiagnosis & prognosisTreatment regimensGenetics & inherited forms

Hospitals counted here

  1. Huashan Hospital Counted in the group total1
  2. Gynecology Hospital, Fudan University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
0.6%Leads under 1 in 100 of China's research papers on Beta thalassaemia New since 2021

Led 2 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
1
Research papers it led
2
Trials it led
2
Share of China's trials
4.3%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Zhongshan Hospital, Fudan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
4.7%Leads about 1 in 21 of China's research papers on NMOSD

Led 23 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
1
Research papers it led
23
Trials it led
2
Share of China's trials
2.6%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025
ThemesAntibodies & diagnosisBiologic drugsRelapse prevention

Hospitals counted here

  1. Huashan Hospital23
  2. Jing'an District Centre Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.2023Neurology(R) neuroimmunology & neuroinflammationFree full text
  2. Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.2022JAMA network openFree full text
  3. Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study.2025Frontiers in immunologyFree full text
  4. Eculizumab for the acute attack of neuromyelitis optica spectrum disorder.2025Frontiers in immunologyFree full text
  5. KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort.2025Journal of neurology, neurosurgery, and psychiatry
Trials on ClinicalTrials.gov6
  1. HANDLE-a Real World Study on Satralizumab in NMOSDRecruitingNCT06829524Lead sponsorStart 2025-03
  2. A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)RecruitingNCT05199688Study sitePhase 3Start 2026-05
  3. Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)Not yet recruitingNCT07266051Study siteStart 2025-12
  4. BLAZE-Limiting Approach in NMOSDCompletedNCT06888622Lead sponsorStart 2023-10
  5. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08
  6. An Open Label Study of the Effects of SHR1459 in NMOSDs PatientsCompletedNCT04670770Study sitePhase 2Start 2021-01

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
2.4%Leads about 1 in 41 of China's research papers on IgG4-RD ▼ from 4.9%

Led 6 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 0020242025: 112025
ThemesTreatment & relapseHead, eye socket & salivary glands

Hospitals counted here

  1. Zhongshan Hospital, Fudan University4
  2. Fudan University Shanghai Cancer Center Counted in the group total1
  3. Eye & ENT Hospital of Fudan University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
6.6%Leads about 1 in 15 of China's research papers on Myasthenia gravis ▼ from 9.2%

Led 33 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
5
Research papers it led
33
Trials it led
7
Share of China's trials
7.6%
Share of the world's papers
1.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesAntibodies & diagnosisBiologic & complement drugsCrisis & intensive care

Hospitals counted here

  1. Huashan Hospital31
  2. Zhongshan Hospital, Fudan University1
  3. Children's Hospital of Fudan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis.2026Clinical immunology (Orlando, Fla.)
  2. Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.2025Frontiers in immunologyFree full text
  3. The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.2025Neurocritical care
  4. Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study.2025Clinical immunology (Orlando, Fla.)
  5. Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.2025Frontiers in immunologyFree full text
Trials on ClinicalTrials.gov6
  1. EFG vs IVIG in TAMGNot yet recruitingNCT07231523Lead sponsorPhase 3Start 2025-12
  2. An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia GravisNot yet recruitingNCT06759948Lead sponsorPhase 1Start 2025-02
  3. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Lead sponsorStart 2024-02
  4. Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in ChinaRecruitingNCT04535843Lead sponsorStart 2024-02
  5. Construction of A Multimodal Digital Assessment Model for Myasthenia GravisRecruitingNCT07146425Lead sponsorStart 2023-08
  6. An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia GravisNot yet recruitingNCT07818291Study sitePhase 1Start 2026-09

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
6.7%Leads about 1 in 15 of China's research papers on Moyamoya

Led 24 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
1
Research papers it led
24
Trials it led
3
Share of China's trials
9.1%
Share of the world's papers
1.9%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025
ThemesImaging & blood flowRevascularisation surgeryStroke & bleeding outcomes

Hospitals counted here

  1. Huashan Hospital17
  2. Children's Hospital of Fudan University2
  3. Huadong Hospital, Fudan University2
  4. Eye & ENT Hospital of Fudan University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Inhalational versus intravenous anesthetic for cerebrovascular accident outcomes after surgical revascularization for adult moyamoya disease.2025BMC anesthesiologyFree full text
  2. Post-anesthesia care unit delirium in children with moyamoya disease undergoing indirect revascularization: incidence and risk factors.2025Korean journal of anesthesiologyFree full text
  3. The cerebellar glucose metabolism in moyamoya vasculopathy and its correlation with neurocognitive performance after cerebral revascularization surgery: a [18F]FDG PET study.2025European journal of nuclear medicine and molecular imagingFree full text
  4. Individualised evaluation based on pathophysiology for moyamoya vasculopathy: application in surgical revascularisation.2024Stroke and vascular neurologyFree full text
  5. Transient ischemic attack after indirect revascularization surgery for pediatric patients with moyamoya disease: A retrospective study of intraoperative blood pressure.2023Anaesthesia, critical care & pain medicine
Trials on ClinicalTrials.gov5
  1. Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES TrialNot yet recruitingNCT07286110Lead sponsorPhase 1Start 2025-12
  2. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Study siteStart 2026-08
  3. Registry of Multicenter Brain-Heart Comorbidity in ChinaRecruitingNCT05961748Study siteStart 2012-01
  4. Neurocognitive and Radiological Assessments in Adult Moyamoya Undergoing SurgeryStatus unknownNCT02305407Lead sponsorN/AStart 2016-03
  5. The Adult Hemorrhagic Moyamoya Surgery StudyStatus unknownNCT02319980Lead sponsorPhase 3Start 2015-05

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
0.5%Leads under 1 in 100 of China's research papers on Wilson disease ▼ from 3.1%

Led 1 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025
ThemesGenetics (ATP7B)Treatment (chelation, zinc)

Hospitals counted here

  1. Zhongshan Hospital, Fudan University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Penicillamine-induced degenerative dermopathy in a patient with Wilson's disease.2023The Australasian journal of dermatology
Trials on ClinicalTrials.gov1
  1. China Registry for Genetic / Metabolic Liver DiseasesRecruitingNCT03131427Study siteStart 2015-06

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
9.8%Leads about 1 in 10 of China's research papers on Biliary atresia ▼ from 12.8%

Led 21 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
3
Research papers it led
21
Trials it led
4
Share of China's trials
20.0%
Share of the world's papers
2.8%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025
ThemesDisease mechanismsScreening & diagnosisLong-term outcomes

Hospitals counted here

  1. Children's Hospital of Fudan University21

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effect of Adjuvant Steroid Therapy in Type 3 Biliary Atresia: A Single-Center, Open-Label, Randomized Controlled Trial.2023Annals of surgeryRCT
  2. Preventive effect of prophylactic intravenous antibiotics against cholangitis in biliary atresia: a randomized controlled trial.2021Pediatric surgery internationalRCT
  3. Development and validation of a minimally invasive diagnostic model for biliary atresia using artificial intelligence.2025World journal of pediatrics : WJPFree full text
  4. Establishment of Biliary Atresia Prognostic Classification System via Survival-Based Forward Clustering - A New Biliary Atresia Classification.2025Indian journal of pediatrics
  5. Incidence and outcome of biliary atresia in Shanghai, China from 2015 to 2016: a cohort study.2024BMJ paediatrics openFree full text
Trials on ClinicalTrials.gov6
  1. Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai PortoenterostomyRecruitingNCT05925309Lead sponsorN/AStart 2023-07
  2. Preoperative Serum FGF19 in the Prognosis of Biliary AtresiaRecruitingNCT05848310Lead sponsorStart 2023-10
  3. High Medium-chain Triglyceride Nutritional Support in Infants With Biliary AtresiaRecruitingNCT05072626Lead sponsorStart 2021-10
  4. A Peer Support Network System Construction for the Primary Caregivers of Children With Biliary AtresiaCompletedNCT05503394Lead sponsorN/AStart 2022-08
  5. Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomyTerminatedNCT06121375Study sitePhase 2/Phase 3Start 2024-09
  6. An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaActive, not recruitingNCT05426733Study sitePhase 3Start 2022-07

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.1%Leads about 1 in 88 of China's research papers on Anti-NMDA receptor encephalitis ▼ from 4.0%

Led 3 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Gynecology Hospital, Fudan University1
  2. Children's Hospital of Fudan University1
  3. Huashan Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
19.8%Leads about 1 in 5 of China's research papers on Takayasu arteritis

Led 37 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
2
Research papers it led
37
Trials it led
6
Share of China's trials
24.0%
Share of the world's papers
4.6%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 2220242025: 002025

Hospitals counted here

  1. Zhongshan Hospital, Fudan University33

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study.2024Rheumatology (Oxford, England)RCT
  2. Comment on: Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis. Reply.2024Rheumatology (Oxford, England)
  3. PET vascular activity score for predicting new angiographic lesions in patients with Takayasu arteritis: a Chinese cohort study.2023Rheumatology (Oxford, England)
  4. Comment on: A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG-PET/CT: a Chinese cohort study: reply.2022Rheumatology (Oxford, England)
  5. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study.2022Annals of the rheumatic diseases
Trials on ClinicalTrials.gov6
  1. A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's ArteritisRecruitingNCT06498089Lead sponsorPhase 4Start 2024-06
  2. A Pilot Study in Severe Patients With Takayasu Arteritis.RecruitingNCT04300686Lead sponsorPhase 4Start 2020-03
  3. Comparison of Tofacitinib and Methotrexate in Takayasu's ArteritisStatus unknownNCT05102448Lead sponsorPhase 4Start 2021-11
  4. Efficiency of Methotrexate and Tofacitinib in Mild and Moderate PatientsStatus unknownNCT04299971Lead sponsorPhase 4Start 2020-03
  5. Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery StenosisStatus unknownNCT04137614Lead sponsorN/AStart 2019-11
  6. The Registry Study of Takayasu Arteritis in East ChinaStatus unknownNCT03893136Lead sponsorStart 2016-11

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.8%Leads about 1 in 55 of China's research papers on Idiopathic pulmonary fibrosis ▲ from 0.3%

Led 18 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
18
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Huashan Hospital7
  2. Fifth People's Hospital of Fudan University3
  3. Zhongshan Hospital, Fudan University3
  4. Jing'an District Central Hospital2
  5. Shanghai Pudong Hospital1
  6. Zhongshan-Xuhui Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects.2025Clinical and translational scienceRCT
  2. Physical activity and idiopathic pulmonary fibrosis: A prospective cohort study in UK Biobank and Mendelian randomization analyses.2024Respiratory medicine and research
  3. Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume.2022Respiratory research
  4. Baicalin inhibits the Akt/mTOR/ULK1 signaling pathway to activate autophagy and ameliorate pulmonary fibrosis.2026International immunopharmacology
  5. Iron dysregulation and ferroptosis are associated with pulmonary fibrosis: Insight from idiopathic pulmonary fibrosis, systemic sclerosis, and COVID-19 patients.2025Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
Trials on ClinicalTrials.gov6
  1. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  2. A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07909655Study sitePhase 2Start 2026-11
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  4. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  5. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  6. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
2.8%Leads about 1 in 35 of China's research papers on Amyotrophic lateral sclerosis

Led 22 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
22
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 1120242025: 112025

Hospitals counted here

  1. Huashan Hospital10
  2. Zhongshan Hospital, Fudan University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
29.1%Leads about 1 in 3 of China's research papers on Spinal muscular atrophy ▼ from 51.8%

Led 16 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
0
Research papers it led
16
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.9%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. Huashan Hospital11
  2. Children's Hospital of Fudan University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Teaching NeuroImages: Hirayama Disease With Symmetric Atrophy of Bilateral Distal Upper Extremities.2021Neurology
  2. Effectiveness and safety of Risdiplam for types 1-3 spinal muscular atrophy in a single center.2025BMC neurology
  3. Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China.2025BMC pediatrics
  4. Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.2024Journal of neurology
  5. The role of leisure-time physical activity in maintaining cervical lordosis after anterior cervical fusion and its impact on the motor function in patients with hirayama disease: a retrospective cohort analysis.2023BMC musculoskeletal disorders
Trials on ClinicalTrials.gov6
  1. A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)RecruitingNCT07221669Study sitePhase 3Start 2026-04
  2. A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type IRecruitingNCT07554924Study sitePhase 1/Phase 2Start 2026-07
  3. A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMAEnrolling by invitationNCT06588803Study siteStart 2025-03
  4. Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular AtrophyEnrolling by invitationNCT06888661Study siteEarly phase 1Start 2025-03
  5. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01
  6. Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1Status unknownNCT05614531Study sitePhase 1/Phase 2Start 2023-02

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
1.4%Leads about 1 in 73 of China's research papers on Fabry disease New since 2021

Led 1 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
1
Research papers it led
1
Trials it led
2
Share of China's trials
14.3%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Children's Hospital of Fudan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Pompe disease

庞贝病
3.3%Leads about 1 in 30 of China's research papers on Pompe disease ▼ from 6.2%

Led 1 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
11.1%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Huashan Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. High-risk screening for late-onset Pompe disease in China: An expanded multicenter study.2025Journal of inherited metabolic disease
Trials on ClinicalTrials.gov1
  1. Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)Not yet recruitingNCT06178432Lead sponsorEarly phase 1Start 2023-12

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.9%Leads about 1 in 53 of China's research papers on Duchenne muscular dystrophy ▲ from 1.0%

Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

Hospitals counted here

  1. Children's Hospital of Fudan University2
  2. Huashan Hospital1
  3. Zhongshan Hospital, Fudan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
11.4%Leads about 1 in 9 of China's research papers on Behçet disease

Led 28 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
28
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025

Hospitals counted here

  1. Huadong Hospital, Fudan University24
  2. Zhongshan Hospital, Fudan University2
  3. Children's Hospital of Fudan University1
  4. Huashan Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.9%Leads about 1 in 53 of China's research papers on IgA nephropathy

Led 14 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025

Hospitals counted here

  1. Huashan Hospital6
  2. Zhongshan Hospital, Fudan University4
  3. Children's Hospital of Fudan University2
  4. Minhang Hospital1
  5. Huadong Hospital, Fudan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Exploring the shared molecular mechanisms of primary hypertension and IgA vasculitis through a case report and combining bioinformatics analysis.2025Frontiers in immunology
  2. Serum soluble interleukin-2 receptor alpha may predict tubulointerstitial inflammatory cell infiltration and short-term disease progression in immunoglobin A nephropathy.2024Immunologic research
  3. Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study.2024Kidney & blood pressure research
  4. Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.2024Renal failure
  5. IgA nephropathy: gut microbiome regulates the production of hypoglycosilated IgA1 via the TLR4 signaling pathway.2024Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Trials on ClinicalTrials.gov6
  1. A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.RecruitingNCT07203404Study siteEarly phase 1Start 2025-07
  2. A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney DiseasesNot yet recruitingNCT07389499Study siteEarly phase 1Start 2027-08
  3. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  4. A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy SubjectsCompletedNCT07035665Study sitePhase 1Start 2025-06
  5. Comparison of HRS-5965 Capsules and Tablets in Healthy SubjectsCompletedNCT06490991Study sitePhase 1Start 2024-07
  6. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
2.0%Leads about 1 in 50 of China's research papers on Osteogenesis imperfecta New since 2021

Led 2 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Zhongshan Hospital, Fudan University1
  2. Children's Hospital of Fudan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Peroral endoscopic myotomy for treatment of achalasia in a patient with congenital osteogenesis imperfecta and scoliosis.2023Endoscopy
  2. Clinical severity prediction in children with osteogenesis imperfecta caused by COL1A1/2 defects.2022Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
2.5%Leads about 1 in 40 of China's research papers on Hirschsprung disease ▲ from 1.5%

Led 4 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Children's Hospital of Fudan University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症
8.9%Leads about 1 in 11 of China's research papers on Inherited epidermolysis bullosa New since 2021

Led 5 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.5%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. Children's Hospital of Fudan University2
  2. Huashan Hospital2
  3. Zhongshan Hospital, Fudan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
1.7%Leads about 1 in 59 of China's research papers on Familial adenomatous polyposis ▼ from 5.9%

Led 1 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
33.3%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Fudan University Shanghai Cancer Center1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. A one-stop approach to diagnosing hereditary colorectal cancer in the Chinese population.2023Journal of gastroenterology and hepatology
Trials on ClinicalTrials.gov1
  1. Efficacy of Vitamin B1 in Familial Adenomatous Polyposis Patients.Enrolling by invitationNCT06649825Lead sponsorN/AStart 2024-01

PubMed searchClinicalTrials.gov